Legal status | |
---|---|
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C42H62N2O4S |
Molar mass | 691.03 g·mol−1 |
3D model (JSmol) | |
| |
|
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]
Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]
It appears that development of BMS-955176 has been terminated.[6]